Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma (NCT07241546) | Clinical Trial Compass
RecruitingPhase 2
Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma
Canada36 participantsStarted 2026-03-30
Plain-language summary
The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Clinically stable, mild atopic asthma (FEV1 ≥70% predicted)
* Established allergy confirmed by positive skin prick test at screening
* Willing and able to perform lung function tests and other study-related procedures
* Participants of childbearing potential must consent to use a method of highly-effective contraception in addition to a condom during the study and for at least 90 days following the end of study or last investigational product administration, whichever is later
Exclusion Criteria:
* Concomitant diagnosis of a clinically important pulmonary disease other than asthma
* Use of corticosteroids, immunosuppressives, or anti-inflammatory medications that interfere with inhaled challenges or inflammation, or chronic use of any other medication for treatment of allergic asthma
* History or current medical condition contraindicating methacholine challenge
Note: Additional inclusion/exclusion criteria may apply per protocol.
What they're measuring
1
Change from Baseline Over Time in Maximum Area of Reactance